Sage Journals: Discover world-class research

Abstract

Objective

This study was performed to examine the possible association of iron overload with infectious complications and survival among liver transplant recipients.

Methods

We conducted a systematic review and meta-analysis of studies published in the PubMed, Embase, Web of Science, and Cochrane Library databases up to September 2022. Hazard ratios (HRs) and 95% confidence intervals (CIs) were extracted to estimate the association of iron overload with infectious outcomes and overall survival after liver transplantation.

Results

Eight studies involving 2817 recipients met the inclusion criteria. Iron overload was strongly associated with an increased risk of infection after liver transplantation (HR, 1.66; 95% CI, 1.03–2.68). An increase in the serum ferritin level was associated with an increased risk of infection after liver transplantation (HR, 1.44; 95% CI, 1.09–1.91). Iron overload was a significant predictor of worse overall survival (HR, 1.35; 95% CI, 1.11–1.64). In addition, a high serum ferritin level was significantly associated with an increased risk of death (HR, 1.34; 95% CI, 1.10–1.64).

Conclusion

Iron overload may be associated with a higher risk of infectious complications and a worse prognosis among liver transplant recipients.

Keywords

Iron liver transplantation infection prognosis meta-analysis survival

Introduction

Liver transplantation (LT) is often a life-saving treatment for the increasing number of patients with end-stage liver disease. Because of improvements in surgical techniques, immunosuppression strategies, and post-LT management of complications, the mortality rate associated with LT has steadily declined. In Western countries, the survival rates after LT are 83% at 1 year and 71% at 5 years.¹ However, the use of immunosuppressants increases the risk of postoperative infection, potentially resulting in severe morbidity. Infection caused by bacteria, fungi, and viruses remains one of the leading causes of morbidity and mortality among transplant recipients worldwide.^1–3 Knowledge of modifiable risk factors and their potentially reversible causes is essential to develop targeted preventive strategies.

The Model for End-stage Liver Disease (MELD) was introduced in 2002 and has since become the most widely used method of organ allocation in LT.⁴ Additional factors have also been found to be associated with LT-related morbidity and mortality, such as the serum sodium level,⁵ renal function,⁶ sarcopenia,⁷ and the ferritin level.⁸ Iron is a critical resource for microorganisms, but it can also increase the virulence of microbes and impair the host immune response.^9,10 Ferritin is the major iron storage protein, and it reflects the cumulative iron stores in the bone marrow and tissues.¹¹ An increase in the serum ferritin level can occur in the context of many hepatic diseases, such as chronic hepatitis C, treatment-naive autoimmune hepatitis, and nonalcoholic steatohepatitis.^12,13 However, ferritin is also an acute-phase reactant and is influenced by systemic inflammation.¹⁴ Excess body iron is present in the liver and is very closely correlated with the total body iron stores.^15,16 Histologically, iron is not visible in healthy liver tissue. Iron staining of liver biopsy specimens can be used to assess the hepatic iron concentration and has been linked to the severity of liver diseases.^17,18 Iron homeostasis plays a critical role in cellular physiology. From an immunological point of view, iron accumulation in macrophages renders them more conducive to supporting the survival and colonization of viruses with other pathogenic microorganisms.¹⁹

Although previous clinical studies have linked iron overload to an increased risk of bacterial infection and mortality after LT,^8,20–26 the evidence supporting this hypothesis remains unclear. We therefore performed a meta-analysis of systematic reviews focused on the potential impact of iron metabolism imbalance on patient outcomes.

Materials and methods

We performed this meta-analysis in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.²⁷

Data sources and search

Two investigators independently screened the abstracts and reviewed the full texts of studies to determine their eligibility. We searched the PubMed, Embase, Cochrane Library, and Web of Science databases from inception to 30 September 2022 using the following terms: “liver transplantation,” “liver grafting,” “hepatic transplantation,” and “iron.” Relevant systematic reviews and cited references were also searched manually. The search was limited to studies published in English. After the initial search, duplicate articles were removed. The titles and abstracts were then screened to progressively exclude nonrelevant studies. The final list of included studies was determined through consensus, and any disagreements were resolved by consulting a third assessor.

Selection criteria

We developed the following inclusion criteria to select studies in accordance with the PICOS framework (population, intervention, comparator, outcomes, and study design).

Studies were included in the systematic review if they met the following criteria: (1) the study investigated the infection and mortality rates after LT; (2) the study evaluated the predictive ability of one or more iron-related markers in blood or hepatic explants (serum ferritin level, stainable hepatic iron, and hepatic iron index) for postoperative infection and mortality in liver transplant recipients; (3) definite infection was defined as laboratory isolation of an organism from a normally sterile site combined with symptoms of infection; and (4) possible infection was defined as the presence of signs and symptoms of infection warranting empirical treatment with antibiotics in the absence of confirmatory evidence.

The exclusion criteria were (1) study abstracts, conference abstracts, editorials, review articles, letters, animal studies, and case studies and (2) studies reporting incomplete or insufficient data.

Data extraction and management

Two reviewers independently extracted the following data into a prepiloted Microsoft Excel-based data extraction form: study characteristics (study design, study period, location, sample size, measures of iron load, and outcome measures) and participant characteristics (number of participants, etiology of liver disease, and pre-LT MELD score). We were unable to quantify differences by race/ethnicity because these data were not available. Next, we extracted the hazard ratio (HR) and 95% confidence interval (CI) associated with the iron load and outcome (infection or death). When critical data were missing or unclear in the published reports, we attempted to contact the authors. Any disagreements in the data extraction process were resolved by discussion.

Quality assessment

Two authors independently assessed the methodological quality of the included studies using the Newcastle–Ottawa Scale (NOS).²⁸ The NOS is a 9-point scale that consists of three domains: selection, comparability, and outcome assessment. Studies scoring 7 to 9 points were considered to be of high quality, those scoring 4 to 6 points were of moderate quality, and those scoring 0 to 3 points were of low quality.

Statistical analysis

The primary outcome measures were the HRs for infection events and OS. These data were derived from the reported HRs, together with the 95% CIs from the original studies. If the HR and 95% CI were not reported, they were derived indirectly from Kaplan–Meier curves using the methods described by Tierney et al.²⁹ Pooled HR estimates were generated according to the categories noted above. In the absence of heterogeneity among individual studies, we used a fixed-effects model to pool the data; otherwise, a random-effects model was applied. Heterogeneity among studies was estimated by Cochran’s Q test and the I² statistic (I² > 50% indicated substantial heterogeneity). Publication bias was assessed using funnel plots. We also performed sensitivity analyses to examine the robustness of the results. All statistical analyses were performed using RevMan version 5.3 (Cochrane Collaboration).

Results

Identification of studies and study characteristics

The PRISMA flow chart shown in Figure 1 summarizes the literature search and study selection processes. The literature search initially yielded 2819 articles. After removing duplicates, 1018 articles remained. After screening the titles and abstracts, 1005 nonrelevant records were excluded, leaving 14 records for full-text review. Ultimately, eight studies involving 2817 patients met the inclusion criteria for the current systematic review. The overall quality of the eight studies was moderate, and the NOS scores ranged from 7 to 8.

Figure 1.

PRISMA diagram showing identification of eligible studies and reasons for exclusion.

All eight studies^8,20–26 investigated the relationship of iron overload with infection and survival of patients after LT. A summary of the patients’ baseline information is presented in Table 1. Three studies^20,21,23 estimated the correlations between iron overload markers (serum ferritin and stainable iron in the hepatic explant) and susceptibility to infection (cytomegalovirus (CMV) disease, invasive fungal infection, bacteremia) after LT. Mortality outcomes were described in six studies,^{8,20,22,24–26} which reported the OS HR for serum ferritin and stainable iron in the hepatic explant.

Table 1.

Baseline characteristics of included studies.

Source	Country	Trial design	Study period	Iron markers	Outcome after OLT	Total patients	Etiology of liver disease	MELD score, mean (range)
Chow et al.²⁰ (2010)	USA	RT	1987–1990	Increased serum ferritin (ng/mL) after OLT	CMV disease, bacteremia, invasive fungal infection, 1-year mortality	109	PSC, ALD, PBC, other (no hemochromatosis)	NR
Chow et al.²¹ (2017)	USA	RT	2009–2012	Increased serum ferritin (ng/mL) after LT	Intra-abdominal infection, blood infection, Clostridium difficile colitis, urinary tract infection, CMV disease, Candida esophagitis, surgical site infection	128	HCC, ALD, NASH, viral hepatitis C, viral hepatitis B	23.1 (8.3)
Fallet et al.²² (2020)	France	RT	2001–2011	Serum ferritin of >400 µg/L before OLT	OS (95-month follow-up)	553	ALD, viral hepatitis C/B, PSC, PBC, AH, hemochromatosis, HCC, other	15.1 (10.6–20.7)
Alexander et al.²³ (2006)	USA	RT	1997–1999	Stainable hepatic iron (Perls Prussian blue stain in explanted liver)	Invasive fungal infection	153	HCC, CLD, other	15 (6–40)
Brandhagen et al.²⁴ (2000)	USA	RT	1985–1995	Hepatic iron index of >1.9	OS (4.4-year follow-up)	328	HCC, cryptogenic liver disease, ALD, viral hepatitis C, viral hepatitis B, alpha-1 antitrypsin deficiency, Wilson’s disease, AH, PSC, PBC	NR
Weismüller et al.²⁵ (2011)	Germany	RT	2003–2008	Serum ferritin of >365 µg/L before LT	OS (1639-day follow-up)	328	HCC, ALD, viral hepatitis C, viral hepatitis B, PSC, PBC, AH	13.9 (7.86–22.46)
Al-Freah et al.²⁶ (2013)	UK	RT	2000–2007	Serum ferritin of >300 µg/L before LT	OS (3.64-year follow-up)	1079	ALD, viral hepatitis, CLD, AH, HCC	14 (6–40)
Walker et al.⁸ (2010)	Australia	RT	2000–2006	Serum ferritin of >400 µg/L before LT	OS (1-year follow-up)	139	HCC, ALD, viral hepatitis, PSC, PBC	15.4 (10.3–20.5)

RT, retrospective; MELD, Model for End-stage Liver Disease; ALD, alcoholic liver disease; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; HCC, hepatocellular carcinoma; NASH, non-alcoholic steatohepatitis; AH, autoimmune hepatitis; CLD, cholestatic liver disease; LT, liver transplantation; OLT, orthotopic liver transplantation; CMV, cytomegalovirus; OS, overall survival; NR, not reported

Iron overload and infectious complications in LT

The infectious events after LT are summarized in Table 1. Three studies^20,21,23 involving 390 patients examined the relationship between the serum ferritin level, stainable iron in the hepatic explant, and infectious complications after LT. Among these studies, the definition of infectious complications (intra-abdominal infection, bloodstream infection, skin and soft tissue infection, urinary tract infection, CMV disease, and invasive fungal infection) included the time to first infection being at least 1 week after LT.²¹

Overall, 103 (26.4%) of these patients had at least one infection event, including bacteremia, CMV disease, and invasive fungal infection. Iron overload was strongly associated with an increased risk of infection after LT (HR, 1.66; 95% CI, 1.03–2.68; p = 0.04) (Figure 2(a)). We analyzed the results using a fixed-effects model because the estimated degree of heterogeneity between studies was 50%. The subgroup analyses showed that an increase in the serum ferritin level was independently associated with an increased risk of infection after LT (HR, 1.44; 95% CI, 1.09–1.91; p = 0.01), with no heterogeneity (I² = 0%,) (Figure 2(b)).

Figure 2.

Forest plot for association between infectious complications after liver transplantation and iron overload. Subgroup analysis was performed according to iron storage indicators. (a) Increased serum ferritin level after liver transplantation and iron stainable by Perls Prussian blue stain in the explanted livers and (b) increased serum ferritin level after liver transplantation.

Iron overload and survival in LT

In total, six articles involving 2536 participants examined the relationship between death and iron markers. Of these, five studies involving 2208 patients estimated the association between the preoperative^22,25,26 or postoperative²⁰ serum ferritin level and OS. One study²⁴ assessed the association between the hepatic iron index of hepatic explants and OS. We first examined the overall effect of perioperative stored iron markers on survival using a fixed-effects model. The pooled HRs showed that high levels of stored iron markers were significantly correlated with a poor prognosis (HR, 1.35; 95% CI, 1.11–1.64; p = 0.003), and heterogeneity was low (I² = 34%) (Figure 3(a)).

Figure 3.

Forest plots for the association between overall survival and iron overload. Subgroup analysis was performed according to iron storage indicators. (a) Serum ferritin level and iron stainable by Perls Prussian blue stain in the explanted livers. (b) Serum ferritin level and (c) serum ferritin level before liver transplantation.

A previous study showed that the serum ferritin level can indicate the degree of ischemia/reperfusion injury in LT.³⁰ We performed a subgroup analysis using a fixed-effects model to determine whether the serum ferritin level can be evaluated as a noninvasive prognostic indicator on its own. Three studies assessed the serum ferritin level during the evaluation of patients undergoing LT.^22,25,26 In another study, the serum ferritin level was examined within 72 hours after LT.²⁰

The pooled results revealed that a high preoperative or postoperative serum ferritin level was significantly associated with an increased risk of death (HR, 1.34; 95% CI, 1.10–1.64; p = 0.004), and heterogeneity was low (I² = 46%) (Figure 3(b)). Pooled analysis using a random-effects model showed that higher preoperative serum ferritin levels were also associated with poor survival (HR, 1.54; 95% CI, 1.06–2.25; p = 0.003), with moderate heterogeneity (I² = 53%) (Figure 3 (c)).

Publication bias and sensitivity analyses

We tested for publication bias by assessing the symmetry of the funnel plots, and no substantial publication bias was found (Figure 4(a–e)). Sensitivity analyses were conducted to test the robustness of the overall estimated results. The removal of individual studies one at a time did not appreciably change the results.

Figure 4.

Funnel plots for publication bias. (a, b) Infectious complications and (c–e) Mortality.

Discussion

This systematic review provides several lines of evidence indicating significantly increased risks of infection and death after LT in patients with a high serum ferritin level or hepatic explant iron overload. We included eight studies^8,20–26 involving 2817 patients who had undergone LT. Six^{8,20–22,25,26} of these studies examined the serum ferritin level in LT patients, four^8,22,25,26 studies evaluated the serum ferritin level before LT, and two^20,21 studies evaluated the serum ferritin level postoperatively. Different pathogen profiles were reported among three studies,^20,21,23 including bacteria, fungi, and viruses. Two studies showed that an increased serum ferritin level is an independent risk factor for any infection after LT.^20,21 In addition, Alexander et al.²³ found a significant correlation between stainable hepatic iron in explants and invasive fungal infection after LT. Another important finding of the present study is that LT patients with iron overload had a higher risk of death than those without iron overload. The subgroup analysis of serum ferritin as a predictor showed that LT patients with a high serum ferritin level during the perioperative period have poor outcomes.

Liver transplant recipients are on long-term immunosuppressive regimens and are at particular risk of postoperative infection.³ Infectious complications remain a leading cause of mortality after LT. The latest European surveys from 1968 to 2017 revealed that 4.1% of children who underwent LT died of infection.³¹ The most common types infection after LT are bacterial infection (accounting for approximately 70% of all infections), fungal infection, and viral infection.³² We identified the MELD score as a key consideration for operative urgency in LT. Nevertheless, a previous meta-analysis revealed several risk factors for all-cause infection and mortality that are not directly reflected by the MELD score, such as biliary complications, ascites, atelectasis, and the bilirubin level.^33,34 Furthermore, patients with hepatocellular carcinoma undergo LT at a rate that is not restricted by the MELD score.³⁵ This finding suggests that there may still be unidentified causal risk factors driving these associations.

Iron is the most abundant transition metal ion in biological systems and is an essential nutrient for nearly all organisms and cells.³⁶ The iron distribution is intimately linked to host defense against pathogens.³⁷ The main indicators of the iron distribution are the serum ferritin level, hemoglobin level, total iron banding capacity, and transferrin saturation level.³⁸ The liver iron concentration is also a reliable indicator of total body iron, but its measurement is invasive.³⁹ Previous meta-analyses showed that that a long operation time, incompatible blood type, operative blood loss, and biliary complications are risk factors for bloodstream infection after LT.³⁴ Recent evidence has suggested that the serum ferritin level is often increased in patients with liver disease.¹³ One study revealed that iron overload triggers the development of nonalcoholic steatohepatitis by interrupting the liver redox balance.⁴⁰ Patients with nonalcoholic steatohepatitis are more likely than patients without nonalcoholic steatohepatitis to die of sepsis after LT.⁴¹ Kowdley et al.⁴² found that hepatic iron overload is associated with poor clinical survival after LT. A similar finding was reported in patients who underwent hematopoietic stem cell transplantation.⁴³ In addition, excess iron promotes the rapid growth of bacteria in blood and may enhance susceptibility to sepsis.⁴⁴ The invading pathogen must obtain iron from the host, but host nutritional immunity maintains a limited amount of free iron, thereby interrupting iron acquisition by pathogens.⁴⁵ However, this relationship remains controversial. Stuart et al.⁴⁶ reported that the hepatic iron concentration is not the most important determinant of the outcome after LT.

In the present study, we evaluated the effects of host iron on the clinical outcomes of LT and found that iron overload is a risk factor for infectious complications and poor survival in transplant recipients. However, our study had several limitations. First, all the included studies were retrospective in design, limiting our ability to perform a subgroup analysis to explore potential sources of heterogeneity. Second, the endpoint definitions, study populations, follow-up intervals, and measures of iron storage varied among the studies, thereby increasing heterogeneity. Third, the precise biological significance of the serum ferritin level in LT recipients, including its relationship to iron overload and inflammation, remains unclear. Further research is needed to investigate the role of iron metabolism in the pathogenesis of infection in LT recipients. Finally, the number of included studies was small, and we were unable to evaluate the difference in predictive ability between serum tests and iron staining of grafts through meta-regression.

Conclusion

The current meta-analysis demonstrated the usefulness of serum ferritin measurement and iron staining in the grafted liver for evaluating the probability of infection and predicting mortality in patients undergoing LT. Additional research is necessary to determine whether this new strategy can further inform targeted intervention strategies to reduce the risk of infection and death in liver transplant recipients. Furthermore, future research should examine the risks of adverse events associated with iron overload in LT.

Supplemental Material

sj-pdf-1-imr-10.1177_03000605241232920 - Supplemental material for Association of iron overload with infectious complications in liver transplant recipients: a systematic review and meta-analysis

Supplemental material, sj-pdf-1-imr-10.1177_03000605241232920 for Association of iron overload with infectious complications in liver transplant recipients: a systematic review and meta-analysis by Jingpo Zhang, Bingzheng Yan and Xin Shi in Journal of International Medical Research

Footnotes

Author contributions

Jingpo Zhang and Xin Shi designed the study. Jingpo Zhang and Bingzheng Yan performed the literature search, study selection, data extraction, and statistical analyses. Jingpo Zhang and Xin Shi wrote the first draft of the manuscript. All authors contributed to the interpretation of the data and critically reviewed the manuscript.

Data availability statement

All data used in this study are freely available by contacting the corresponding author.

Declaration of conflicting interest

The authors disclose no potential conflicts of interest. All authors have agreed to publish this manuscript.

Ethics statement

This study was approved by The Ethics Committee of the First Hospital of Hebei Medical University.

Funding

The authors received no specific funding for this work.

ORCID iD

Xin Shi

References

Chen

Pang

Shen

, et al. High mortality associated with gram-negative bacterial bloodstream infection in liver transplant recipients undergoing immunosuppression reduction. World J Gastroenterol 2020; 26: 7191–7203.

Friedrich

Krempl

Schamoni

, et al. Multidrug-resistant bacteria and disease progression in patients with end-stage liver disease and after liver transplantation. J Gastrointestin Liver Dis 2019; 28: 303–310.

Fishman

JA.

Infection in solid-organ transplant recipients. N Engl J Med 2007; 357: 2601–2614.

Kamath

Wiesner

Malinchoc

, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464–470.

Biggins

Rodriguez

Bacchetti

, et al. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology 2005; 41: 32–39.

Uguen

Jezequel

Ropert

, et al. Pretransplant renal function according to CKD-EPI cystatin C equation is a prognostic factor of death after liver transplantation. Liver Int 2016; 36: 547–554.

Van Vugt

JLA

Alferink

LJM

Buettner

, et al. A model including sarcopenia surpasses the MELD score in predicting waiting list mortality in cirrhotic liver transplant candidates: a competing risk analysis in a national cohort. J Hepatol 2018; 68: 707–714.

Walker

Stuart

Ryan

, et al. Serum ferritin concentration predicts mortality in patients awaiting liver transplantation. Hepatology 2010; 51: 1683–1691.

Schrettl

Bignell

Kragl

, et al. Siderophore biosynthesis but not reductive iron assimilation is essential for Aspergillus fumigatus virulence. J Exp Med 2004; 200: 1213–1219.

10.

Holbein

Ang

MTC

Allan

, et al. Iron-withdrawing anti-infectives for new host-directed therapies based on iron dependence, the Achilles’ heel of antibiotic-resistant microbes. Environ Chem Lett 2021; 19: 2789–2808.

11.

Das

Schwartz

Barthel

, et al. Microbial metabolite signaling is required for systemic iron homeostasis. Cell Metab 2020; 31: 115–130.e6.

12.

Martín-González

Pelazas-González

Fernández-Rodríguez

, et al. Ferritin and liver fibrosis among patients with chronic hepatitis C virus infection. J Trace Elem Med Biol 2020; 61: 126542.

13.

Kowdley

Belt

Wilson

, NASH Clinical Research Networket al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2012; 55: 77–85.

14.

Kalantar-Zadeh

Rodriguez

Humphreys

MH.

Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 141–149.

15.

Zhang

Ghosh

Ollivierre

, et al. Ferroportin deficiency in erythroid cells causes serum iron deficiency and promotes hemolysis due to oxidative stress. Blood 2018; 132: 2078–2087.

16.

Angelucci

Brittenham

McLaren

, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000; 343: 327–331.

17.

Turlin

Deugnier

Iron overload disorders. Clin Liver Dis 2002; 6: 481–496 viii.

18.

Guo

Liu

, et al. Iron overload in alcoholic liver disease: underlying mechanisms, detrimental effects, and potential therapeutic targets. Cell Mol Life Sci 2022; 79: 201.

19.

Drakesmith

Prentice

Viral infection and iron metabolism. Nat Rev Microbiol 2008; 6: 541–552.

20.

Chow

Werner

Ruthazer

, et al. Increased serum iron levels and infectious complications after liver transplantation. Clin Infect Dis 2010; 51: e16–e23.

21.

Chow

JKL

Ganz

Ruthazer

, et al. Iron-related markers are associated with infection after liver transplantation. Liver Transpl 2017; 23: 1541–1552.

22.

Fallet

Rayar

Landrieux

, et al. Iron metabolism imbalance at the time of listing increases overall and infectious mortality after liver transplantation. World J Gastroenterol 2020; 26: 1938–1949.

23.

Alexander

Limaye

, et al. Association of hepatic iron overload with invasive fungal infection in liver transplant recipients. Liver Transpl 2006; 12: 1799–1804.

24.

Brandhagen

Alvarez

Therneau

, et al. Iron overload in cirrhosis-HFE genotypes and outcome after liver transplantation. Hepatology 2000; 31: 456–460.

25.

Weismüller

Kirchner

Scherer

, et al. Serum ferritin concentration and transferrin saturation before liver transplantation predict decreased long-term recipient survival. Hepatology 2011; 54: 2114–2124.

26.

Al-Freah

Kriese

Fau-Foxton

, et al. The association of pretransplant ferritin level with waiting list and post-transplant survival. Does ferritin actually predict outcome? Transpl Int 2013; 26: 1070–1079.

27.

Moher

Liberati

Tetzlaff

, PRISMA Groupet al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Med 2009; 6: e1000097.

28.

Stang

Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25: 603–605.

29.

Tierney

Stewart

Ghersi

, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007; 8: 16.

30.

Wakiya

Sanada

Urahashi

, et al. Impact of the serum ferritin concentration in liver transplantation. Liver Transpl 2015; 21: 1419–1427.

31.

Baumann

Karam

Adam

, European Liver and Intestine Transplant Association (ELITA) and all ELTR contributing centerset al. Prognosis of children undergoing liver transplantation: a 30-year European study. Pediatrics 2022; 150: e2022057424.

32.

Fishman

JA.

Infections in immunocompromised hosts and organ transplant recipients: essentials. Liver Transpl 2011; 17: S34–S37.

33.

Zhang

, et al. Risk factor for lung infection in recipients after liver transplantation: a meta-analysis. Artif Organs 2021; 45: 289–296.

34.

Liu

, et al. Risk factors of bloodstream infections in recipients after liver transplantation: a meta-analysis. Infection 2019; 47: 77–85.

35.

Kremers

Van Ijperen

Fau-Kim

, et al. MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS status 1 patients. Hepatology 2004; 39: 764–769.

36.

Zygiel

Nolan

EM.

Transition metal sequestration by the host-defense protein calprotectin. Annu Rev Biochem 2018; 87: 621–643.

37.

Casu

Nemeth

Rivella

Hepcidin agonists as therapeutic tools. Blood 2018; 131: 1790–1794.

38.

Zhou

The associations of iron related biomarkers with risk, clinical severity and mortality in SARS-CoV-2 patients: a meta-analysis. Nutrients 2022; 14: 3406.

39.

Brittenham

Badman

, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Workshop. Noninvasive measurement of iron: report of an NIDDK workshop. Blood 2003; 101: 15–19.

40.

Videla

Valenzuela

Perspectives in liver redox imbalance: toxicological and pharmacological aspects underlying iron overloading, nonalcoholic fatty liver disease, and thyroid hormone action. Biofactors 2022; 48: 400–415.

41.

Wang

Riaz

, et al. Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2014; 12: 394–402.e1.

42.

Kowdley

Brandhagen

Gish

, National Hemochromatosis Transplant Registryet al. Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry. Gastroenterology 2005; 129: 494–503.

43.

Sucak

Yegin

Ozkurt

, et al. Iron overload: predictor of adverse outcome in hematopoietic stem cell transplantation. Transplant Proc 2010; 42: 1841–1848.

44.

Cherayil

BJ.

The role of iron in the immune response to bacterial infection. Immunol Res 2011; 50: 1–9.

45.

Hood

Skaar

EP.

Nutritional immunity: transition metals at the pathogen-host interface. Nat Rev Microbiol 2012; 10: 525–537.

46.

Stuart

Fletcher

Clouston

, et al. Increased hepatic iron and cirrhosis: no evidence for an adverse effect on patient outcome following liver transplantation. Hepatology 2000; 32: 1200–1207.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.07 MB